tetano
Editor, Senior Moderator
NPJ Vaccines
. 2025 May 14;10(1):96.
doi: 10.1038/s41541-025-01133-w. Human naïve B cells show evidence of anergy and clonal redemption following vaccination
Brian L P Dizon[SUP] 1 2 [/SUP], Prasida Holla[SUP] 3 [/SUP], Evan C Mutic[SUP] 4 [/SUP], Paul Schaughency[SUP] 5 [/SUP], Susan K Pierce[SUP] 6 [/SUP]
Affiliations
In an era of predicted emerging pandemics, the production of effective vaccines may require an in-depth understanding of the biology of human naive B (B[SUB]N[/SUB]) cells. Here we provide evidence that the majority of B[SUB]N[/SUB] cells expressed CD73, an ecto-5'-nucleotidase often associated with immune cell suppression, and demonstrated features of anergy, including an IgM[SUP]low[/SUP]IgD[SUP]+[/SUP] surface phenotype, reduced calcium flux in response to IgM crosslinking, and increased PTEN expression. Analysis of antibody sequences encoded by the inherently autoreactive V[SUB]H[/SUB]4-34 heavy chain produced by plasmablasts seven days following influenza vaccination showed that in younger but not in older individuals, anergic B[SUB]N[/SUB] cells provided a reservoir of B cells capable of responding to vaccination by somatic mutation, resulting in diversification and loss of autoreactivity. These results suggest that effective human vaccines may require the ability to awaken or 'redeem' anergic B[SUB]N[/SUB] cells that can be repurposed to participate in pathogen-specific responses.
. 2025 May 14;10(1):96.
doi: 10.1038/s41541-025-01133-w. Human naïve B cells show evidence of anergy and clonal redemption following vaccination
Brian L P Dizon[SUP] 1 2 [/SUP], Prasida Holla[SUP] 3 [/SUP], Evan C Mutic[SUP] 4 [/SUP], Paul Schaughency[SUP] 5 [/SUP], Susan K Pierce[SUP] 6 [/SUP]
Affiliations
- PMID: 40368926
- PMCID: PMC12078529
- DOI: 10.1038/s41541-025-01133-w
In an era of predicted emerging pandemics, the production of effective vaccines may require an in-depth understanding of the biology of human naive B (B[SUB]N[/SUB]) cells. Here we provide evidence that the majority of B[SUB]N[/SUB] cells expressed CD73, an ecto-5'-nucleotidase often associated with immune cell suppression, and demonstrated features of anergy, including an IgM[SUP]low[/SUP]IgD[SUP]+[/SUP] surface phenotype, reduced calcium flux in response to IgM crosslinking, and increased PTEN expression. Analysis of antibody sequences encoded by the inherently autoreactive V[SUB]H[/SUB]4-34 heavy chain produced by plasmablasts seven days following influenza vaccination showed that in younger but not in older individuals, anergic B[SUB]N[/SUB] cells provided a reservoir of B cells capable of responding to vaccination by somatic mutation, resulting in diversification and loss of autoreactivity. These results suggest that effective human vaccines may require the ability to awaken or 'redeem' anergic B[SUB]N[/SUB] cells that can be repurposed to participate in pathogen-specific responses.